NCT01470456 - Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

September 30, 2014

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

SAR3419

Pharmaceutical form:solution for infusion Route of administration: Intravenous

DRUG

rituximab

Pharmaceutical form:solution for infusion Route of administration: intravenous

Trial Locations (13)

Investigational Site Number 040002, Graz

Investigational Site Number 250011, Marseille

Investigational Site Number 250009, Dijon

Investigational Site Number 250010, Montpellier

Investigational Site Number 250005, Rennes

Investigational Site Number 250008, Nantes

Investigational Site Number 250006, Lille

Investigational Site Number 250001, Pierre-Bénite

Investigational Site Number 250007, Paris

Investigational Site Number 250003, Rouen

Investigational Site Number 250004, Créteil

Investigational Site Number 250002, Villejuif

Investigational Site Number 578001, Oslo